Intest Res.  2024 Jul;22(3):250-285. 10.5217/ir.2024.00060.

Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023

• Wu JF
• Yen HH
• Wang HY
• Chang TA
• Chang CH
• Chang CW
• Chao TH
• Chou JW
• Chou YH
• Chuang CH
• Hsu WH
• Hsu TC
• Huang TY
• Hung TI
• Le PH
• Lin CC
• Lin CC
• Lin CP
• Lin JK
• Lin WC
• Ni YH
• Shieh MJ
• Shih IL
• Shun CT
• Tsai TJ
• Wang CY
• Weng MT
• Wong JM
• Wu DC
• Wei SC

• KMID: 2558188
• DOI: http://doi.org/10.5217/ir.2024.00060

Abstract

Crohn’s disease (CD) is a chronic, fluctuating inflammatory condition that primarily affects the gastrointestinal tract. Although the incidence of CD in Taiwan is lower than that in Western countries, the severity of CD presentation appears to be similar between Asia and the West. This observation indicates the urgency for devising revised guidelines tailored to the unique reimbursement system, and patient requirements in Taiwan. The core objectives of these updated guidelines include the updated treatment choices and the integration of the treat-to-target strategy into CD management, promoting the achievement of deep remission to mitigate complications and enhance the overall quality of life. Given the diversity in disease prevalence, severity, insurance policies, and access to medical treatments in Taiwan, a customized approach is imperative for formulating these guidelines. Such tailored strategies ensure that international standards are not only adapted but also optimized to local contexts. Since the inception of its initial guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease (TSIBD) has acknowledged the importance of continuous revisions for incorporating new therapeutic options and evolving disease management practices. The latest update leverages international standards and recent research findings focused on practical implementation within the Taiwanese healthcare system.

Keyword

Crohn disease; Management; Guidelines; Consensus; Taiwan

Figure

• 

  Fig. 1. A recommended algorithm for Crohn’s disease (CD) treatment. aThe majority of the studies showing the efficacy of inducing remission are conducted in the pediatric population. However, the evidence in adults is insufficient; bSC or IM 25 mg/wk; c0.5-1.0 mg/kg (max dose 60 mg/day, max duration 28 days); dRemission definition CDAI <150; eAdvanced therapeutics include infliximab, adalimumab, ustekinumab, risankizumab, and upadacitinib. CDAI, Crohn’s Disease Activity Index; EEN, exclusive enteral nutrition; CDED, Crohn’s disease exclusion diet; PEN, partial enteral nutrition; MTX, methotrexate; 5-ASA, aminosalicylates.

Reference

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017; 389:1741–1755.

2. Loftus EV. Crohn’s disease: why the disparity in mortality? Gut. 2006; 55:447–449.

3. Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013; 7:e206–e213.

4. Wei SC, Lin MH, Tung CC, et al. A nationwide populationbased study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan. BMC Gastroenterol. 2013; 13:166.

5. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110:1324–1338.

6. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142:46–54.

7. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140:1785–1794.

8. Kuo CJ, Yu KH, See LC, et al. The trend of inflammatory bowel diseases in Taiwan: a population-based study. Dig Dis Sci. 2015; 60:2454–2462.

9. Wang LH, Yang YJ, Cheng WC, Wang WM, Lin SH, Shieh CC. Higher risk for hematological malignancies in inflammatory bowel disease: a nationwide population-based study in Taiwan. Am J Gastroenterol. 2016; 111:1313–1319.

10. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asiapacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013; 145:158–165.

11. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1. Diagnosis and medical management. J Crohns Colitis. 2017; 11:3–25.

12. Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2. Surgical management and special situations. J Crohns Colitis. 2017; 11:135–149.

13. Ooi CJ, Makharia GK, Hilmi I, et al. Asia Pacific consensus statements on Crohn’s disease. Part 1: definition, diagnosis, and epidemiology (Asia Pacific Crohn’s disease consensus: Part 1). J Gastroenterol Hepatol. 2016; 31:45–55.

14. Ooi CJ, Makharia GK, Hilmi I, et al. Asia-Pacific consensus statements on Crohn’s disease. Part 2: management. J Gastroenterol Hepatol. 2016; 31:56–68.

15. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009; 104:465–483.

16. Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021; 56:489–526.

17. Koh SJ, Hong SN, Park SK, et al. Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease. Intest Res. 2023; 21:43–60.

18. Lan JY. Achieving and sustaining universal health coverage: fiscal reform of the National Health Insurance in Taiwan. Appl Health Econ Health Policy. 2017; 15:717–731.

19. Wei SC, Chang TA, Chao TH, et al. Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res. 2017; 15:285–310.

20. Yen HH, Weng MT, Tung CC, et al. Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study. Intest Res. 2019; 17:54–62.

21. National Health Insurance Administration, Ministry of Health and Welfare. Taiwan catastrophic card registry [Internet]. c2024. [cited 2024 Jun 6]. https://www.nhi.gov.tw/ch/cp5031-7696a-3027-1.html.

22. Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: east meets west. J Gastroenterol Hepatol. 2020; 35:380–389.

23. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017; 152:313–321.

24. Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflamm Bowel Dis. 2015; 21:623–630.

25. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009; 44:659–665.

26. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017; 15:857–863.

27. Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis. 2011; 17:2558–2565.

28. Vegh Z, Burisch J, Pedersen N, et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. J Crohns Colitis. 2014; 8:1506–1515.

29. Rönnblom A, Holmström T, Tanghöj H, Karlbom U, Thörn M, Sjöberg D. Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009. Scand J Gastroenterol. 2016; 51:1339–1344.

30. Su HY, Gupta V, Day AS, Gearry RB. Rising incidence of inflammatory bowel disease in Canterbury, New Zealand. Inflamm Bowel Dis. 2016; 22:2238–2244.

31. Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012; 18:1164–1176.

32. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019; 13:144–164.

33. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68:s1–s106.

34. Łodyga M, Eder P, Gawron-Kiszka M, et al. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol. 2021; 16:257–296.

35. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A metaanalysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015; 110:444–454.

36. Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers. 2020; 6:22.

37. Pimentel M, Chang M, Chow EJ, et al. Identification of a prodromal period in Crohn’s disease but not ulcerative colitis. Am J Gastroenterol. 2000; 95:3458–3462.

38. Veauthier B, Hornecker JR. Crohn’s disease: diagnosis and management. Am Fam Physician. 2018; 98:661–669.

39. Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013; 10:585–595.

40. Weng MT, Lin KL, Huang YL, et al. Epidemiology, disease course, and clinical outcomes of perianal fistulas and fissures Crohn’s disease: a nationwide population-based study in Taiwan. Crohns Colitis 360. 2023; 5:otad035.

41. Chang MH, Chou JW, Chen SM, et al. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. Mol Med Rep. 2014; 10:522–526.

42. E Penna FG, Rosa RM, da Cunha PF, de Souza SC, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn’s disease. BMC Gastroenterol. 2020; 20:35.

43. Cantoro L, Monterubbianesi R, Falasco G, et al. The earlier you find, the better you treat: red flags for early diagnosis of inflammatory bowel disease. Diagnostics (Basel). 2023; 13:3183.

44. Lin WC, Wong JM, Tung CC, et al. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol. 2015; 21:13566–13573.

45. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013; 7:827–851.

46. Lee JM, Lee KM. Endoscopic diagnosis and differentiation of inflammatory bowel disease. Clin Endosc. 2016; 49:370–375.

47. Fausel RA, Kornbluth A, Dubinsky MC. The first endoscopy in suspected inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2016; 26:593–610.

48. Limsrivilai J, Pausawasdi N. Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases. Intest Res. 2021; 19:21–32.

49. Pratap Mouli V, Munot K, Ananthakrishnan A, et al. Endoscopic and clinical responses to anti-tubercular therapy can differentiate intestinal tuberculosis from Crohn’s disease. Aliment Pharmacol Ther. 2017; 45:27–36.

50. Weng MT, Wei SC, Lin CC, et al. Seminar report from the 2014 Taiwan Society of Inflammatory Bowel Disease (TSIBD) spring forum (May 24th, 2014): Crohn’s disease versus intestinal tuberculosis infection. Intest Res. 2015; 13:6–10.

51. Banerjee R, Ali RA, Wei SC, Adsul S. Biologics for the management of inflammatory bowel disease: a review in tuberculosis-endemic countries. Gut Liver. 2020; 14:685–698.

52. Ran Z, Wu K, Matsuoka K, et al. Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 2021; 36:637–645.

53. Kedia S, Das P, Madhusudhan KS, et al. Differentiating Crohn’s disease from intestinal tuberculosis. World J Gastroenterol. 2019; 25:418–432.

54. Sakuraba A, Iwao Y, Matsuoka K, et al. Endoscopic and pathologic changes of the upper gastrointestinal tract in Crohn’s disease. Biomed Res Int. 2014; 2014:610767.

55. de Melo SW, Di Palma JA. The role of capsule endoscopy in evaluating inflammatory bowel disease. Gastroenterol Clin North Am. 2012; 41:315–323.

56. Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2010; 105:1240–1249.

57. Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn’s disease. Am J Gastroenterol. 2006; 101:954–964.

58. Kopylov U, Seidman EG. Role of capsule endoscopy in inflammatory bowel disease. World J Gastroenterol. 2014; 20:1155–1164.

59. Kopylov U, Carter D, Eliakim AR. Capsule endoscopy and deep enteroscopy in irritable bowel disease. Gastrointest Endosc Clin N Am. 2016; 26:611–627.

60. Pennazio M, Spada C, Eliakim R, et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2015; 47:352–376.

61. Yen HH, Chang CW, Chou JW, Wei SC. Balloon-assisted enteroscopy and capsule endoscopy in suspected small bowel Crohn’s disease. Clin Endosc. 2017; 50:417–423.

62. Islam RS, Leighton JA, Pasha SF. Evaluation and management of small-bowel tumors in the era of deep enteroscopy. Gastrointest Endosc. 2014; 79:732–740.

63. Feuerbach S. MRI enterography: the future of small bowel diagnostics? Dig Dis. 2010; 28:433–438.

64. Guglielmo FF, Anupindi SA, Fletcher JG, et al. Small bowel Crohn disease at CT and MR enterography: imaging atlas and glossary of terms. Radiographics. 2020; 40:354–375.

65. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013; 7:556–585.

66. Ho IK, Cash BD, Cohen H, et al. Radiation exposure in gastroenterology: improving patient and staff protection. Am J Gastroenterol. 2014; 109:1180–1194.

67. Yang CT, Yen HH, Chen YY, Su PY, Huang SP. Radiation exposure among patients with inflammatory bowel disease: a single-medical-center retrospective analysis in Taiwan. J Clin Med. 2022; 11:5050.

68. Peloquin JM, Pardi DS, Sandborn WJ, et al. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2008; 103:2015–2022.

69. Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology. 2009; 251:751–761.

70. Kucharzik T, Wittig BM, Helwig U, et al. Use of intestinal ultrasound to monitor Crohn’s disease activity. Clin Gastroenterol Hepatol. 2017; 15:535–542.

71. Villanacci V, Reggiani-Bonetti L, Salviato T, et al. Histopathology of IBD colitis: a practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD). Pathologica. 2021; 113:39–53.

72. Langner C, Magro F, Driessen A, et al. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch. 2014; 464:511–527.

73. Cheng YM, Hsieh TH, Wang CC, Kao JH. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease. JHEP Rep. 2023; 5:100836.

74. Rahier JF, Magro F, Abreu C, et al. Second European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014; 8:443–468.

75. Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2017; 32:769–777.

76. Loras C, Gisbert JP, Mínguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010; 59:1340–1346.

77. Park SH, Yang SK, Lim YS, et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis. 2012; 18:2004–2010.

78. Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol. 2021; 27:3762–3779.

79. Beaugerie L, Rahier JF, Kirchgesner J. Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020; 18:1324–1335.

80. Taiwan Centers for Disease Control. Tuberculosis [Internet]. c2024. [cited 2024 Jun 6]. https://www.cdc.gov.tw/En/Category/ListContent/bg0g_VU_Ysrgkes_KRUDgQ?uaid=0WialNbsh7SEGERJLa29FA.

81. Horsburgh CR, Rubin EJ. Clinical practice: latent tuberculosis infection in the United States. N Engl J Med. 2011; 364:1441–1448.

82. Taiwan Centers for Disease Control. Taiwan guidelines for TB diagnosis & treatment [Internet]. c2017. [cited 2024 Jun 6]. https://www.cdc.gov.tw/Category/ListContent/6ms9nH64dI6Jqdu_4025cw?uaid=5cube3WpXWqs8unt-Vv5MA.

83. Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. Lancet Infect Dis. 2022; 22:250–264.

84. Fehily SR, Al-Ani AH, Abdelmalak J, et al. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022; 56:6–27.

85. Olivera PA, Lasa JS, Zubiaurre I, et al. Opportunistic infections in patients with inflammatory bowel disease treated with advanced therapies: a systematic review and meta-analysis of randomized controlled trials. J Crohns Colitis. 2023; 17:199–210.

86. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55:749–753.

87. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002; 122:512–530.

88. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr. 1991; 12:439–447.

89. Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010; 105:2085–2092.

90. Caio G, Lungaro L, Caputo F, et al. Nutritional treatment in Crohn’s disease. Nutrients. 2021; 13:1628.

91. Bischoff SC, Escher J, Hébuterne X, et al. ESPEN practical guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 2020; 39:632–653.

92. Forbes A, Escher J, Hébuterne X, et al. ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 2017; 36:321–347.

93. Yanai H, Levine A, Hirsch A, et al. The Crohn’s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn’s disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol. 2022; 7:49–59.

94. Chapman TP, Frias Gomes C, Louis E, Colombel JF, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020; 52:73–84.

95. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020; 14:4–22.

96. Hart A, Ng SC, Watkins J, et al. The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink. Ann Gastroenterol. 2020; 33:500–507.

97. Gade AK, Douthit NT, Townsley E. Medical management of Crohn’s disease. Cureus. 2020; 12:e8351.

98. Kuenzig ME, Rezaie A, Kaplan GG, et al. Budesonide for the induction and maintenance of remission in Crohn’s disease: systematic review and meta-analysis for the Cochrane Collaboration. J Can Assoc Gastroenterol. 2018; 1:159–173.

99. Chande N, Abdelgadir I, Gregor J. The safety and tolerability of methotrexate for treating patients with Crohn’s disease. J C lin Gastroenterol. 2011; 45:599–601.

100. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000; 342:1627–1632.

101. Nielsen OH, Steenholdt C, Juhl CB, Rogler G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: a systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine. 2020; 20:100271.

102. Cassinotti A, Batticciotto A, Parravicini M, et al. Evidencebased efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications. Therap Adv Gastroenterol. 2022; 15:17562848221085889.

103. Panés J, López-Sanromán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013; 145:766–774.

104. Jeong DY, Kim S, Son MJ, et al. Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review. Autoimmun Rev. 2019; 18:439–454.

105. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997; 337:1029–1035.

106. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006; 130:323–333.

107. Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2016; 10:CD000545.

108. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010; 362:1383–1395.

109. Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019; 20:2529.

110. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016; 375:1946–1960.

111. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013; 369:711–721.

112. D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022; 399:2015–2030.

113. Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023; 388:1966–1980.

114. Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn’s disease. Gastroenterology. 1997; 113:118–126.

115. Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. 2020; 51:831–842.

116. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015; 386:1825–1834.

117. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017; 390:2779–2789.

118. Verstockt B, Parkes M, Lee JC. How do we predict a patient’s disease course and whether they will respond to specific treatments? Gastroenterology. 2022; 162:1383–1395.

119. Ben-Horin S, Novack L, Mao R, et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology. 2022; 162:482–494.

120. Klomberg RC, van der Wal HC, Aardoom MA, et al. Improved clinical outcomes with early anti-tumour necrosis factor alpha therapy in children with newly diagnosed Crohn’s disease: real-world data from the international prospective PIBD-SETQuality inception cohort study. J Crohns Colitis. 2024; 18:738–750.

121. Ungaro RC, Naegeli AN, Choong CK, et al. Early use of biologics reduces healthcare costs in Crohn’s disease: results from a united states population-based cohort. Dig Dis Sci. 2024; 69:45–55.

122. D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008; 371:660–667.

123. Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024; 9:415–427.

124. Maté-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000; 12:1227–1233.

125. de Boer NK, Peyrin-Biroulet L, Jharap B, et al. Thiopurines in inflammatory bowel disease: new findings and perspectives. J Crohns Colitis. 2018; 12:610–620.

126. Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014; 2014:CD006884.

127. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014; 39:1349–1362.

128. Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017; 45:1291–1302.

129. Vermeire S, Loftus EV, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn’s disease. J Crohns Colitis. 2017; 11:412–424.

130. Vermeire S, D’Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn’s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022; 16:27–38.

131. Rutgeerts P, Gasink C, Chan D, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn’s disease. Gastroenterology. 2018; 155:1045–1058.

132. Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IMUNITI trial. Clin Gastroenterol Hepatol. 2022; 20:578–590.

133. Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, doubleblind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022; 399:2031–2046.

134. Wu JF. Therapeutic drug monitoring of biologics for patients with inflammatory bowel diseases: how, when, and for whom? Gut Liver. 2022; 16:515–524.

135. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021; 160:2496–2508.

136. Chapman TP, Gomes CF, Louis E, Colombel JF, Satsangi J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020; 5:63–79.

137. Siegel CA, Thompson KD, Walls D, et al. Perspectives from patients and gastroenterologists on de-escalating therapy for Crohn’s disease. Clin Gastroenterol Hepatol. 2021; 19:403–405.

138. Louis E. Stopping anti-TNF in Crohn’s disease remitters: pros and cons: the pros. Inflamm Intest Dis. 2022; 7:64–68.

139. Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016; 111:632–647.

140. Molander P, Färkkilä M, Salminen K, et al. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014; 20:1021–1028.

141. Rieder F, Latella G, Magro F, et al. European Crohn’s and Colitis Organisation topical review on prediction, diagnosis and management of fibrostenosing Crohn’s disease. J Crohns Colitis. 2016; 10:873–885.

142. Lin WC, Chou JW, Yen HH, et al. Outcomes of limited period of adalimumab treatment in moderate to severe Crohn’s disease patients: Taiwan Society of Inflammatory Bowel Disease Study. Intest Res. 2017; 15:487–494.

143. Lin WC, Tai WC, Chang CH, et al. Real-world evidence of effectiveness and safety of vedolizumab for inflammatory bowel disease in Taiwan: a prospective nationwide registry (VIOLET) study. Inflamm Bowel Dis. 2023; 29:1730–1740.

144. Ponsioen CY, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017; 2:785–792.

145. de Groof EJ, Stevens TW, Eshuis EJ, et al. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial. Gut. 2019; 68:1774–1780.

146. Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCOESCP consensus on surgery for Crohn’s disease. J Crohns Colitis. 2018; 12:1–16.

147. Rombeau JL, Barot LR, Williamson CE, Mullen JL. Preoperative total parenteral nutrition and surgical outcome in patients with inflammatory bowel disease. Am J Surg. 1982; 143:139–143.

148. Rochelle TL, Fidler H. The importance of illness perceptions, quality of life and psychological status in patients with ulcerative colitis and Crohn’s disease. J Health Psychol. 2013; 18:972–983.

149. Bojic D, Bodger K, Travis S. Patient reported outcome measures (PROMs) in inflammatory bowel disease: new data. J Crohns Colitis. 2017; 11:S576–S585.

150. Khanna R, Zou G, D’Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity. Aliment Pharmacol Ther. 2015; 41:77–86.

151. Ghosh S, Louis E, Beaugerie L, et al. Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases. Inflamm Bowel Dis. 2017; 23:333–340.

152. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD). Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160:1570–1583.

153. Cappello M, Morreale GC. The role of laboratory tests in Crohn’s disease. Clin Med Insights Gastroenterol. 2016; 9:51–62.

154. Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol. 2019; 15:667–677.

155. Ma C, Battat R, Khanna R, Parker CE, Feagan BG, Jairath V. What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn’s disease activity? Best Pract Res Clin Gastroenterol. 2019; 38-39:101602.

156. Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association between level of fecal calprotectin and progression of Crohn’s disease. Clin Gastroenterol Hepatol. 2019; 17:2269–2276.

157. Plevris N, Fulforth J, Lyons M, et al. Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2021; 19:1835–1844.

158. Reinisch W, Panaccione R, Bossuyt P, et al. Association of biomarker cutoffs and endoscopic outcomes in Crohn’s disease: a post hoc analysis from the CALM study. Inflamm Bowel Dis. 2020; 26:1562–1571.

159. Picco MF, Farraye FA. Targeting mucosal healing in Crohn’s disease. Gastroenterol Hepatol (N Y). 2019; 15:529–538.

160. Mosli M, Alameel T, Sharara AI. Mucosal healing in Crohn’s disease: bull’s eye or bust? The “relative” con position. Inflamm Intest Dis. 2021; 7:42–49.

161. Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn’s disease: what the clinician needs to know. Therap Adv Gastroenterol. 2019; 12:1756284819856865.

162. Colombel JF, D’haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020; 14:254–266.

163. Vespa E, Furfaro F, Allocca M, et al. Endoscopy after surgery in inflammatory bowel disease: Crohn’s disease recurrence and pouch surveillance. Expert Rev Gastroenterol Hepatol. 2020; 14:829–841.

164. Nardone OM, Calabrese G, Testa A, et al. The impact of intestinal ultrasound on the management of inflammatory bowel disease: from established facts toward new horizons. Front Med (Lausanne). 2022; 9:898092.

165. De Cruz P, Hamilton AL, Burrell KJ, Gorelik A, Liew D, Kamm MA. Endoscopic prediction of Crohn’s disease postoperative recurrence. Inflamm Bowel Dis. 2022; 28:680–688.

166. Narula N, Wong EC, Dulai PS, Marshall JK, Jairath V, Reinisch W. The performance of the Rutgeerts score, SES-CD, and MM-SES-CD for prediction of postoperative clinical recurrence in Crohn’s disease. Inflamm Bowel Dis. 2023; 29:716–725.

167. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990; 99:956–963.

168. Rimola J, Torres J, Kumar S, Taylor SA, Kucharzik T. Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut. 2022; 71:2587–2597.

169. Meima-van Praag EM, Buskens CJ, Hompes R, Bemelman WA. Surgical management of Crohn’s disease: a state of the art review. Int J Colorectal Dis. 2021; 36:1133–1145.

170. Garofalo E, Selvaggi F, Spinelli A, et al. Surgical management of complex ileocolonic Crohn’s disease: a survey of IBD colorectal surgeons to assess variability in operative strategy. Int J Colorectal Dis. 2021; 36:1811–1815.

171. Barrett K, Saxena S, Pollok R. Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care. Br J Gen Pract. 2018; 68:497–498.

172. Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol. 2008; 103:2373–2381.

173. Huang W, Tang Y, Nong L, Sun Y. Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn’s disease: a meta-analysis of observational studies. J Crohns Colitis. 2015; 9:293–301.

174. López-Sanromán A. Steroids and postoperative complications in IBD. Curr Drug Targets. 2019; 20:1323–1326.

175. Loureiro AC, Barbosa LE. Appendectomy and Crohn’s disease. J Coloproctol. 2019; 39:373–380.

176. Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J, Frisch M. The risk of developing Crohn’s disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut. 2007; 56:1387–1392.

177. Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology. 2003; 124:40–46.

178. Zhang L, Hu C, Zhang Z, et al. Association between prior appendectomy and the risk and course of Crohn’s disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2023; 47:102090.

179. Carvalho AT, Esberard BC, da Luz Moreira A. Current management of spontaneous intra-abdominal abscess in Crohn’s disease. J Coloproctol. 2018; 38:158–163.

180. Celentano V, Giglio MC, Pellino G, et al. High complication rate in Crohn’s disease surgery following percutaneous drainage of intra-abdominal abscess: a multicentre study. Int J Colorectal Dis. 2022; 37:1421–1428.

181. Barnes EL, Herfarth HH, Sandler RS, et al. Pouch-related symptoms and quality of life in patients with ileal pouch-anal anastomosis. Inflamm Bowel Dis. 2017; 23:1218–1224.

182. Reese GE, Lovegrove RE, Tilney HS, et al. The effect of Crohn’s disease on outcomes after restorative proctocolectomy. Dis Colon Rectum. 2007; 50:239–250.

183. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008; 23:1213–1221.

184. Bolckmans R, Kalman T, Singh S, et al. Does smoking cessation reduce surgical recurrence after primary ileocolic resection for Crohn’s disease? Dis Colon Rectum. 2020; 63:200–206.

185. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn’s disease. Gastroenterology. 1994; 106:643–648.

186. Chen BC, Weng MT, Chang CH, Huang LY, Wei SC. Effect of smoking on the development and outcomes of inflammatory bowel disease in Taiwan: a hospital-based cohort study. Sci Rep. 2022; 12:7665.

187. Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 2016; 150:1568–1578.

188. Nguyen GC, Loftus EV, Hirano I, et al. American Gastroenterological Association institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology. 2017; 152:271–275.

189. Sulz MC, Burri E, Michetti P, et al. Treatment algorithms for Crohn’s disease. Digestion. 2020; 101 Suppl 1:43–57.

190. De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients: a POCER study analysis. Aliment Pharmacol Ther. 2015; 42:867–879.

191. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology. 2000; 118:264–273.

192. Mañosa M, Fernández-Clotet A, Nos P, et al. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn’s disease: results from the ENEIDA registry. Dig Liver Dis. 2023; 55:46–52.

193. Buisson A, Nancey S, Manlay L, et al. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn’s disease. United European Gastroenterol J. 2021; 9:552–560.

194. Odufalu FD, Long M, Lin K, Mahadevan U; PIANO Investigators from the Crohn’s and Colitis Foundation (CCF) Clinical Research Alliance recruited patients for their respective centers for participant enrollment. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut. 2022; 71:1766–1772.

195. Torres J, Chaparro M, Julsgaard M, et al. European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis. 2023; 17:1–27.

196. Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021; 160:1131–1139.

197. Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016; 22:224–233.

198. Meng X, Dunsmore G, Koleva P, et al. The profile of human milk metabolome, cytokines, and antibodies in inflammatory bowel diseases versus healthy mothers, and potential impact on the newborn. J Crohns Colitis. 2019; 13:431–441.

199. Restellini S, Biedermann L, Hruz P, et al. Update on the management of inflammatory bowel disease during pregnancy and breastfeeding. Digestion. 2020; 101 Suppl 1:27–42.

200. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018; 155:696–704.

201. U.S. Food and Drug Administration. RINVOQ® (upadacitinib) extended-release tablets, for oral use [Internet]. c2019. [cited 2024 Jun 6]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211675s008lbl.pdf.

202. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015; 9:107–124.

203. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019; 156:1508–1524.

204. Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018; 4:CD000542.

205. Swaminath A, Feathers A, Ananthakrishnan AN, Falzon L, Li Ferry S. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2017; 46:645–656.

206. Jackman L, Arpe L, O’ Connor G. Exclusive enteral nutrition practices in the management of Crohn’s disease: a cross sectional survey of specialist paediatric dietitians. Clin Nutr ESPEN. 2022; 49:252–255.

207. Cucinotta U, Romano C, Dipasquale V. Diet and nutrition in pediatric inflammatory bowel diseases. Nutrients. 2021; 13:655.

208. Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019; 157:440–450.

209. Légeret C, Furlano R, Köhler H. Therapy strategies for children suffering from inflammatory bowel disease (IBD): a narrative review. Children (Basel). 2022; 9:617.

210. Yu Y, Chen KC, Chen J. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn’s disease: a meta-analysis. World J Pediatr. 2019; 15:26–36.

211. Cushing K, Higgins PD. Management of Crohn disease: a review. JAMA. 2021; 325:69–80.

212. Hong SJ, Zenger C, Pecoriello J, et al. Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy. Inflamm Bowel Dis. 2022; 28:1826–1832.

213. Poullenot F, Amiot A, Nachury M, et al. Comparative risk of incident cancer in patients with inflammatory bowel disease with prior non-digestive malignancy according to immunomodulator: a multicentre cohort study. J Crohns Colitis. 2022; 16:1523–1530.

214. Vedamurthy A, Gangasani N, Ananthakrishnan AN. Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: a retrospective cohort study. Clin Gastroenterol Hepatol. 2022; 20:88–95.

215. Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016; 14:58–64.

216. Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015; 9:945–965.

217. Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis. 2011; 17:1423–1427.

218. Williams GM. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur J Cancer Prev. 2008; 17:169–177.

219. Kobayashi T, Uda A, Udagawa E, Hibi T. Lack of increased risk of lymphoma by thiopurines or biologics in Japanese patients with inflammatory bowel disease: a large-scale administrative database analysis. J Crohns Colitis. 2020; 14:617–623.

220. Hong SJ, Galati J, Katz S. Crohn’s disease of the elderly: unique biology and therapeutic efficacy and safety. Gastroenterol Clin North Am. 2022; 51:425–440.

221. Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis. 2017; 11:263–273.

222. Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA clinical practice update on management of inflammatory bowel disease in elderly patients: expert review. Gastroenterology. 2021; 160:445–451.

223. Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014; 41:974–980.

224. Wan Q, Zhao R, Xia L, et al. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies. J Cancer Res Clin Oncol. 2021; 147:1077–1087.

225. Uchino M, Ikeuchi H, Hata K, et al. Intestinal cancer in patients with Crohn’s disease: a systematic review and metaanalysis. J Gastroenterol Hepatol. 2021; 36:329–336.

226. Chin YH, Jain SR, Lee MH, et al. Small bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. Int J Colorectal Dis. 2022; 37:239–250.

227. Biancone L, Zuzzi S, Ranieri M, et al. Fistulizing pattern in Crohn’s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis. 2012; 6:578–587.

228. Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013; 108:1869–1876.

229. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010; 8:268–274.

230. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011; 141:1612–1620.

231. Stjärngrim J, Ekbom A, Hammar U, Hultcrantz R, Forsberg AM. Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population? Gut. 2019; 68:1588–1596.

232. Porter RJ, Arends MJ, Churchhouse AM, Din S. Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines. J Crohns Colitis. 2021; 15:2131–2141.

233. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006; 23:1097–1104.

234. Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol. 2020; 5:475–484.

235. So J, Tang W, Leung WK, et al. Cancer risk in 2621 Chinese patients with inflammatory bowel disease: a populationbased cohort study. Inflamm Bowel Dis. 2017; 23:2061–2068.

236. Piovani D, Hassan C, Repici A, et al. Risk of cancer in inflammatory bowel diseases: umbrella review and reanalysis of meta-analyses. Gastroenterology. 2022; 163:671–684.

237. Aardoom MA, Joosse ME, de Vries AC, Levine A, de Ridder L. Malignancy and mortality in pediatric-onset inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2018; 24:732–741.

238. Chang M, Chang L, Chang HM, Chang F. Intestinal and extraintestinal cancers associated with inflammatory bowel disease. Clin Colorectal Cancer. 2018; 17:e29–e37.

239. Laukoetter MG, Mennigen R, Hannig CM, et al. Intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg. 2011; 15:576–583.

240. Thomas M, Bienkowski R, Vandermeer TJ, Trostle D, Cagir B. Malignant transformation in perianal fistulas of Crohn’s disease: a systematic review of literature. J Gastrointest Surg. 2010; 14:66–73.

241. Martínez Sánchez ER, Solá Fernández A, Pérez Palacios D, et al. Perianal Crohn’s disease: clinical implications, prognosis and use of resources. Rev Esp Enferm Dig. 2022; 114:254–258.

242. Kobayashi T, Udagawa E, Hibi T. Lack of increased risk of lymphoma with thiopurine therapy regardless of dose and duration of treatment in Japanese patients with inflammatory bowel diseases. Digestion. 2022; 103:169–173.

243. Egberg MD, Zhang X, Smitherman AB, Kappelman MD. Low risk of lymphoma in pediatric patients treated for inflammatory bowel disease. Am J Gastroenterol. 2023; 118:354–359.

244. Dahmus J, Rosario M, Clarke K. Risk of lymphoma associated with anti-TNF therapy in patients with inflammatory bowel disease: implications for therapy. Clin Exp Gastroenterol. 2020; 13:339–350.

245. Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis. 2020; 14:155–168.

246. Shen B, Kochhar G, Navaneethan U, et al. Practical guidelines on endoscopic treatment for Crohn’s disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020; 5:393–405.

247. Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021; 160:2512–2556.

248. Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016; 388:1281–1290.

249. Panés J, García-Olmo D, Van Assche G, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2018; 154:1334–1342.e4.

250. Scott LJ. Darvadstrocel: a review in treatment-refractory complex perianal fistulas in Crohn’s disease. BioDrugs. 2018; 32:627–634.

251. Yassin NA, Askari A, Warusavitarne J, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn’s disease. Aliment Pharmacol Ther. 2014; 40:741–749.

252. Ferretti F, Cannatelli R, Ardizzone S, Maier JA, Maconi G. Ultrasonographic evaluation of intestinal fibrosis and inflammation in Crohn’s disease. The State of the Art. Front Pharmacol. 2021; 12:679924.

253. Lin X, Wang Y, Liu Z, et al. Intestinal strictures in Crohn’s disease: a 2021 update. Therap Adv Gastroenterol. 2022; 15:17562848221104951.

254. Yoo JH, Holubar S, Rieder F. Fibrostenotic strictures in Crohn’s disease. Intest Res. 2020; 18:379–401.

255. Allocca M, Bonifacio C, Fiorino G, et al. Efficacy of tumour necrosis factor antagonists in stricturing Crohn’s disease: a tertiary center real-life experience. Dig Liver Dis. 2017; 49:872–877.

256. Rodríguez-Lago I, Hoyo JD, Pérez-Girbés A, et al. Early treatment with anti-tumor necrosis factor agents improves longterm effectiveness in symptomatic stricturing Crohn’s disease. United European Gastroenterol J. 2020; 8:1056–1066.

257. Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018; 67:53–60.

258. Campos C, Perrey A, Lambert C, et al. Medical therapies for stricturing Crohn’s disease: efficacy and cross-sectional imaging predictors of therapeutic failure. Dig Dis Sci. 2017; 62:1628–1636.

259. Bettenworth D, Gustavsson A, Atreja A, et al. A pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with stricturing Crohn’s disease. Inflamm Bowel Dis. 2017; 23:133–142.

260. Hirai F, Andoh A, Ueno F, et al. Efficacy of endoscopic balloon dilation for small bowel strictures in patients with Crohn’s disease: a nationwide, multi-centre, open-label, prospective cohort study. J Crohns Colitis. 2018; 12:394–401.

261. Singh A, Agrawal N, Kurada S, et al. Efficacy, safety, and long-term outcome of serial endoscopic balloon dilation for upper gastrointestinal Crohn’s disease-associated strictures: a cohort study. J Crohns Colitis. 2017; 11:1044–1051.

262. Winter RW, Burakoff R. How should we treat mild and moderate-severe Crohn’s disease in 2017? A brief overview of available therapies. Expert Rev Gastroenterol Hepatol. 2017; 11:95–97.

263. Bemelman WA, Allez M. The surgical intervention: earlier or never? Best Pract Res Clin Gastroenterol. 2014; 28:497–503.

264. Toh JW, Wang N, Young CJ, et al. Major abdominal and perianal surgery in Crohn’s disease: long-term follow-up of Australian patients with Crohn’s disease. Dis Colon Rectum. 2018; 61:67–76.

265. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn’s disease. Dis Mon. 2018; 64:20–57.

266. Matar M, Shamir R, Turner D, et al. Combination therapy of adalimumab with an immunomodulator is not more effective than adalimumab monotherapy in children with Crohn’s disease: a post hoc analysis of the PAILOT randomized controlled trial. Inflamm Bowel Dis. 2020; 26:1627–1635.

267. Shah Y, Patel D, Khan N. Iron deficiency anemia in IBD: an overlooked comorbidity. Expert Rev Gastroenterol Hepatol. 2021; 15:771–781.

268. Li L, Xu P, Zhang Z, Zhou X, Chen C, Lu C. Platelets can reflect the severity of Crohn’s disease without the effect of anemia. Clinics (Sao Paulo). 2020; 75:e1596.

269. Abomhya A, Tai W, Ayaz S, et al. Iron deficiency anemia: an overlooked complication of Crohn’s disease. J Hematol. 2022; 11:55–61.

270. Hsiao PY, Weng MT, Chang CH, et al. Anemia in inflammatory bowel disease course is associated with patients’ worse outcome. J Formos Med Assoc. 2023; 122:549–556.

271. Mahadea D, Adamczewska E, Ratajczak AE, et al. Iron deficiency anemia in inflammatory bowel diseases: a narrative review. Nutrients. 2021; 13:4008.

272. Bermejo F, Algaba A, Guerra I, et al. Should we monitor vitamin B12 and folate levels in Crohn’s disease patients? Scand J Gastroenterol. 2013; 48:1272–1277.

273. Park YE, Park SJ, Park JJ, Cheon JH, Kim T, Kim WH. Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet’s disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin. BMC Gastroenterol. 2021; 21:32.